Business Wire

GRAFORCE

24.1.2023 19:01:49 CET | Business Wire | Press release

Share
Graforce and Kawasaki Gas Turbine Europe Collaborate on Zero Carbon Heat-Power Cogeneration Solutions

Graforce, Germany’s leading provider of zero carbon hydrogen plants, and Kawasaki Gas Turbine Europe GmbH (Kawasaki), a European gas turbine and heat-power cogeneration business, are cooperating for zero-emission heat and power generation. The joint innovative plant concept combines Graforce's methane electrolysis technology (plasmalysis) with hydrogen turbines from Kawasaki. First customer projects for this zero carbon heat and power solution are in the works.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230123005010/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hydrogen turbines and methane electrolysis are game changers for an electricity-independent zero carbon heat-power cogeneration. (Photo: Business Wire)

“Our joint zero-emission plant is a breakthrough for the decarbonization of both, fossil fuels and manufacturing industries”, explains Dr. Jens Hanke, CTO of Graforce. “This technology generates CO2-free high-temperature heat via hydrogen, the carbon black is used as a raw material in production, and – best of all, the process is self-sufficient and does not need further electricity after having been started. This in turn relieves the strain on power grids.”

Decarbonization of industrial processes
The new plant solution generates hydrogen from biomethane, natural gas, LNG or LPG by methane electrolysis technology. The hydrocarbons will remain the initial source, but instead of being burnt, a high frequency plasma splits the hydrocarbons into CO2-free hydrogen and carbon black.

The hydrogen is converted to electricity in Kawasaki's hydrogen gas turbine and reused for hydrogen production in the plasma electrolyzer. The ultra-high temperature CO2-free exhaust gas from the hydrogen gas turbine can be used in production processes in various industries. Companies that previously generated high-temperature heat with natural gas can significantly increase their overall efficiency while reducing their gas and especially electricity costs.

Carbon black is used as a synthetic raw material for industrial production. This way, CO2 can be sequestered long-term in steel, cement or for soil enhancement. For industries which require both high temperatures and large quantities of carbon black for production this process pays off twice – in terms of climate protection and cost-effectiveness.

Beyond industry, this hydrogen-based heat-power cogeneration plant can be used for CO2-free heating in surrounding urban areas.

Both technologies were awarded with the Innovation Award of the German Gas Industry, in 2020 and 2022.

About
Kawasaki Gas Turbine Europe GmbH
The German company, 100% subsidiary of Kawasaki Heavy Industries, LTD. (Japan), providing natural gas and hydrogen gas turbine generator set to improve the energy efficiency for various industries and to contribute the global environmental conservation. http://www.kawasaki-gasturbine.de/en

Graforce GmbH
Graforce is German hydrogen technology company developing and manufacturing Power-to-X plants to decarbonize fossil energies, industrial sectors and the heat, transport and building sectors. The company is currently in a process to expand its strategic partnerships with financial as well as strategic investors to quickly scale its hydrogen technology worldwide. www.graforce.com/EN

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005010/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye